膀胱尿路上皮癌组织中DNMT1、HMGA2的表达及临床意义

摘要
图/表
参考文献(21)
相关文章 (7)

全文: PDF (422 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的检测膀胱尿路上皮癌（BUC）组织中DNA甲基转移酶1（DNMT1）、高迁移率族蛋白A2（HMGA2）的表达情况，并探讨其临床意义。方法 2010年1月～2012年6月在西安医学院附属宝鸡医院泌尿外科收集BUC癌组织89例和正常膀胱组织45例，免疫组化SP法检测各组织中DNMT1、HMGA2蛋白的表达，分析DNMT1、HMGA2蛋白表达与BUC患者临床病理参数及预后的关系。结果 DNMT1蛋白在BUC癌组织和正常膀胱组织中的阳性表达率分别为70.79%（63/89）和6.67%（3/45），差异有统计学意义（P ＜ 0.05）；HMGA2蛋白在BUC癌组织和正常膀胱组织中的阳性表达率分别为65.17%（58/89）和2.22%（1/45），差异有统计学意义（P ＜ 0.05）。BUC癌组织中，DNMT1蛋白异常表达与患者肿瘤直径、有无淋巴转移和肿瘤临床分期有关（P ＜ 0.05）；HMGA2蛋白异常表达与患者肿瘤直径、组织分化程度和肿瘤临床分期有关（P ＜ 0.05）。DNMT1阳性患者的生存时间明显短于DNMT1阴性患者（χ2=9.634，P = 0.002）；HMGA2阳性患者的生存时间显著低短于HMGA2阴性患者（χ2=4.911，P = 0.027）。结论在BUC癌组织中，DNMT1、HMGA2蛋白呈高表达状态，且均在BUC的肿瘤发生和恶性进展中发挥重要作用，DNMT1、HMGA2可作为BUC预后预测和治疗的潜在靶点。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	魏福奎王耀锋

关键词 ：膀胱尿路上皮癌, DNA甲基转移酶1, 高迁移率族蛋白A2, 病理参数, 预后

Abstract：Objective To detect the protein expressions of the DNA methyltransferase 1 (DNMT1) and high mobility group protein A2 (HMGA2) in the bladder urothelial carcinoma (BUC) tissues and to investigate their clinical significance. Methods From January 2010 to June 2012, 89 cases of BUC cancer tissues and 45 cases of normal bladder tissues were collected from Department of Urology Surgery of Baoji Affiliated Hospital of Xi'an Medical University. The immunohistochemical SP method was used to detect the protein expression of DNMT1 and HMGA2 in each tissue. In addition, the relationship between the protein expression of DNMT1/HMGA2 and the clinical pathologic characteristics and prognosis was analyzed. Results The positive expression rate of DNMT1 in BUC cancer tissues and normal bladder tissues was 70.79% (63/89) and 6.67% (3/45), respectively (P ＜ 0.05). The positive expression rate of HMGA2 in BUC cancer tissues and the normal bladder tissues was 65.17% (58/89) and 2.22% (1/45), respectively (P ＜ 0.05). In BUC cancer tissues, the DNMT1 protein expression was correlated with the tumor diameter, lymph node metastasis status and the clinical stages (P ＜ 0.05), while the HMGA2 protein expression was correlated with the tumor diameter, differentiation grades and the clinical stages (P ＜ 0.05). The DNMT1-positive patients' survival time was much shorter than the DNMT1-negative patients (P ＜ 0.05), while the HMGA2-positive patients' survival time was much shorter than the HMGA2-negative patients (P ＜ 0.05). Conclusion In BUC cancer tissues, the DNMT1 and HMGA2 are both highly expressed, which may play critical roles in the tumor genesis and the development of BUC. DNMT1 and HMGA2 may serve as biomarkers for the prognosis and the therapy of BUC.

Key words： Bladder urothelial carcinoma DNA methyltransferase 1 High mobility group protein A2 Pathological characteristics Prognosis

基金资助:陕西省自然科学基金资助项目（2016JM8078）。

作者简介: 魏福奎（1969.3-），男，副主任医师；研究方向：微创泌尿外科。

引用本文:

魏福奎王耀锋. 膀胱尿路上皮癌组织中DNMT1、HMGA2的表达及临床意义[J]. 中国医药导报, 2017, 14(33): 78-81.
WEI Fukui WANG Yaofeng. Expression of DNMT1 and HMGA2 in the bladder urothelial carcinoma tissues and their clinical significance. 中国医药导报, 2017, 14(33): 78-81.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I33/78

[1] Chakravarthi BV，Nepal S，Varambally S. Genomic and Epigenomic Alterations in Cancer [J]. Am J Pathol，2016， 186（7）：1724-1735.
[2] Friedman N，Rando OJ. Epigenomics and the structure of the living genome [J]. Genome Res，2015，25（10）：1482-1490.
[3] van der Wijst MG，Venkiteswaran M，Chen H，et al. Local chromatin microenvironment determines DNMT activity：from DNA methyltransferase to DNA demethylase or DNA dehydroxymethylase [J]. Epigenetics，2015，10（8）：671-676.
[4] Yang J，Platt LT，Maity B，et al. RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation [J]. Oncotarget，2016，7（43）：69159-69172.
[5] Cattaruzzi G，Altamura S，Tessari MA，et al. The second AT-hook of the architectural transcription factor HMGA2 is determinant for nuclear localization and function [J]. Nucleic Acids Res，2007，35（6）：1751-1760.
[6] Fedele M，Palmieri D，Fusco A. HMGA2：A pituitary tumour subtype-specific oncogene? [J]. Mol Cell Endocrinol，2010， 326（1/2）：19-24.
[7] Xu L，Liao WL，Lu QJ，et al. ANG Promotes Proliferation and Invasion of the Cell of Lung Squamous Carcinoma by Directly Up-Regulating HMGA2 [J]. J Cancer，2016，7（7）：862-871.
[8] Sun M，Gomes S，Chen P，et al. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2 [J]. Oncogene，2014，33（27）：3528-3537.
[9] Piscuoglio S，Zlobec I，Pallante P，et al. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma [J]. Histopathology，2012，60（3）：397-404.
[10] Yang GL，Zhang LH，Bo JJ，et al. Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis HMGA2 as a prognostic marker of bladder cancer [J]. Eur J Surg Oncol，2011，37（3）：265-271.
[11] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[12] Mathieu R，Lucca I，Rouprêt M，et al. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder [J]. Nat Rev Urol，2016，13（8）：471-479.
[13] Amodio N，D'Aquila P，Passarino G，et al. Epigenetic modifications in multiple myeloma：recent advances on the role of DNA and histone methylation [J]. Expert Opin Ther Targets，2017，21（1）：91-101.
[14] Wang S，Wu W，Claret FX. Mutual regulation of microRNAs and DNA methylation in human cancers [J]. Epigenetics，2017，12（3）：187-197.
[15] Li H，Li W，Liu S，et al. DNMT1，DNMT3A and DNMT3B Polymorphisms Associated With Gastric Cancer Risk：A Systematic Review and Meta-analysis [J]. EBioMedicine，2016，13：125-131.
[16] Lee E，Wang J，Yumoto K，et al. DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells，Which Promotes Prostate Cancer Metastasis [J]. Neoplasia，2016，18（9）：553-566.
[17] Plummer R，Vidal L，Griffin M，et al. Phase Ⅰ study of MG98，an oligonucleotide antisense inhibitor of human DNA methyltransferase 1，given as a 7-day infusion in patients with advanced solid tumors [J]. Clin Cancer Res，2009，15（9）：3177-3183.
[18] Wu CT，Wu CF，Lu CH，et al. Expression and function role of DNA methyltransferase 1 in human bladder cancer [J]. Cancer，2011，117（22）：5221-5233.
[19] Dhawan D，Ramos-Vara JA，Hahn NM，et al. DNMT1：an emerging target in the treatment of invasive urinary bladder cancer [J]. Urol Oncol，2013，31（8）：1761-1769.
[20] Shi Z，Li X，Wu D，et al. Silencing of HMGA2 suppresses cellular proliferation，migration，invasion，and epithelial-mesenchymal transition in bladder cancer [J]. Tumour Biol，2016，37（6）：7515-7523.
[21] Ding X，Wang Y，Ma X，et al. Expression of HMGA2 in bladder cancer and its association with epithelial-to-mesenchymal transition [J]. Cell Prolif，2014，47（2）：146-151.